This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Liu Yin JA . Minimal residual disease in acute myeloid leukaemia. Best Pract Res Clin Haematol 2002; 15: 119–135.
van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901–1928.
Stirewalt DL, Radich JP . The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003; 3: 650–665.
Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911–1918.
van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ . Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003; 17: 1013–1034.
Stirewalt DL, Willman CL, Radich JP . Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific. Leuk Res 2001; 25: 1085–1088.
Gilliland DG . Murky waters for MRD detection in AML: flighty FLT3/ITDs. Blood 2002; 100: 2277.
Shih LY, Huang CF, Wu JH, Lin TL, Dunn P, Wang PN et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood 2002; 100: 2387–2392.
Kottaridis PD, Gale RE, Langabeer SE, Frew ME, Bowen DT, Linch DC . Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 2002; 100: 2393–2398.
Germano G, del Giudice L, Palatron S, Giarin E, Cazzaniga G, Biondi A et al. Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring. Leukemia 2003; 17: 1573–1582.
Acknowledgements
Fondazione M Tettamanti, Associazione Italiana per la Ricerca sul Cancro (AIRC), Associazione Paolo Belli. We thank Joanna Upton for her review of the language.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Beretta, C., Gaipa, G., Rossi, V. et al. Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemia. Leukemia 18, 1441–1444 (2004). https://doi.org/10.1038/sj.leu.2403409
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403409
This article is cited by
-
Diagnostic value of highly-sensitive chimerism analysis after allogeneic stem cell transplantation
Bone Marrow Transplantation (2018)
-
FLT3–ITD and its current role in acute myeloid leukaemia
Medical Oncology (2017)
-
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations
Leukemia (2006)